LEE et al v. VOGELSTEIN et al - Page 7




              Interference 104,066                                                                                       
              (Bd. App. & Int. 1988).  We apply the test set forth in § 1.601(n)7 to determine what                      
              constitutes a separate patentable invention.                                                               
                     Turning to the case before us, we find that in neither its belated motion nor in its                
              brief for final hearing does Lee compare of each of its claims designated as                               
              corresponding to the count with each of Vogelstein’s claims designated as                                  
              corresponding to the count and explain how each of said claims defines a separate                          
              patentable invention.  37 C.F.R. §§1.601(j) and (n).  Rather, we find that Lee only                        
              provides sweeping generalizations such as “[n]one of the [Vogelstein] claims is                            
              specifically directed to treating existing cancer in vivo in a mammal [LB, p. 19]”; and                    
              “[n]one of the [Vogelstein] claims specifies the environment of the cell when p53 is                       
              supplied to it...  Lee[’s] claims, in contrast, are directed to methods of treating existing               
              cancers [LB, p. 19].”  Accordingly, we find that Lee’s belated motion fails to satisfy the                 
              procedural requirements of 37 C.F.R. § 1.601(j) and this failure alone is sufficient                       
              ground for denying the motion.8                                                                            


                     7 37 C.F.R. § 1.601(n) states, in relevant part, that                                               
                            Invention “A” is a separate patentable invention with respect to invention                   
                            “B” when invention “A” is new (35 USC 102) and non-obvious (35 USC                           
                            103) in view of invention “B” assuming invention “B” is prior art with                       
                            respect to invention “A.”                                                                    
                     8 We note Lee’s arguments with respect to what was known in the art at the time                     
              the Lee application was filed.  LB, pp. 19-21.  That is, Lee contends that in 1990 it was                  
              unexpected to those of ordinary skill in the art that the insertion of a wild-type p53 gene                
              into a cancer cell which lacked wild-type p53 function would result in the suppression of                  
              the neoplastic phenotype.  Id.  We find these arguments to be misdirected.  The                            
              relevant issue here is whether one of ordinary skill in the art, would understand that                     
              each of Vogelstein’s claims designated as corresponding to the count do, or do not,                        
                                                           7                                                             





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007